Showing 4061-4070 of 5646 results for "".
- CORD Files for Premarket Approval with the FDA for the SC9 IOL for Cataract Surgeryhttps://modernod.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/Cumming Ophthalmic Research and Development (CORD) announced that it has submitted a premarket approval (PMA) application to the FDA for the Model SC9 IOL. The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has over one hundred patents related to IOLs. D
- Sifi Launches EpiColin Glaucoma Supplement in Italyhttps://modernod.com/news/sifi-launches-epicolin-glaucoma-supplement-in-italy/2481276/Sifi announced the launch in Italy of EpiColin, a food supplement dedicated to patients suffering from glaucoma. Following Amiriox and Ecbirio, IOP drugs fully reimbursed by the Italian NHS, EpiColin is the third innovation in the glaucoma therapeutic area introduced by Sifi in th
- NeoLight Launches ROP Risk Management Software ROPCheck.comhttps://modernod.com/news/neolight-launches-rop-risk-management-software-ropcheckcom/2481271/NeoLight announced that it is releasing ROP Check, a software used in digital care coordination for pediatric retinal screening to detect and monitor progression of retinopathy of prematurity (ROP). The launch comes 1 year after NeoLight acquired Phoenix Technology Group, which bro
- Cognition Therapeutics Presents Data Supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-presents-data-supporting-a-phase-2-clinical-trial-with-ct1812-in-geographic-atrophy-secondary-to-dry-amd/2481270/Cognition Therapeutics announced that the scientific rationale, supporting proof-of-concept data and design of the planned phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) will be communicated in an oral presentation at the
- RetinAI Launches Discovery CORE: AI Platform for Retinal Fluid and Layer Segmentationhttps://modernod.com/news/retinai-launches-discovery-core-ai-platform-for-retinal-fluid-and-layer-segmentation/2481269/RetinAI Medical AG has launched Discovery CORE with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and ima
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Study: Form of AMD Strongly Associated With Cardiovascular Diseasehttps://modernod.com/news/study-blinding-eye-disease-strongly-associated-with-serious-forms-of-cardiovascular-disease/2481254/Patients with a specific form of age-related macular degeneration (AMD) are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study
- Sightpath Medical Acquires Accusite Surgicalhttps://modernod.com/news/sightpath-medical-acquires-accusite-surgical/2481253/Sightpath Medical announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Terms of the deal were not disclosed. Founded in 1991, Sightpath Medical delivers custom access to ophthalmic equipment, instruments, and services. Through its patented
- Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date for Pegcetacoplan for GAhttps://modernod.com/news/apellis-announces-fda-acceptance-of-nda-amendment-and-new-pdufa-date-of-february-26-2023-for-pegcetacoplan-for-ga/2481252/Apellis Pharmaceuticals announced that the FDA has accepted Apellis’ unsolicited major amendment to the new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The updated Prescription D
- GenSight Biologics Announces Publication of Results of Lumevoq REFLECT Pivotal Clinical Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial/2481250/GenSight Biologics announced that the neurology journal BRAIN has published efficacy and safety findings at 1.5-year post-treatment in ND4-LHON patients treated with lenadogene nolparvovec (Lumevoq) from the REFLECT pivotal clinical trial. The REF